Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Renato Lauro is active.

Publication


Featured researches published by Renato Lauro.


British Journal of Ophthalmology | 2008

The role of Humphrey Matrix testing in the early diagnosis of retinopathy in type 1 diabetes

Mariacristina Parravano; Francesco Oddone; Davide Mineo; Marco Centofanti; Patrizia Borboni; Renato Lauro; Lucia Tanga; Gianluca Manni

Aim: The aim of the study was to investigate the role of Humphrey Matrix threshold testing in the detection of early functional retinal impairment in subjects with type 1 diabetes mellitus (DM1) without any signs of retinal vasculopathy, and to investigate the relationship between both functional and structural retinal parameters and metabolic control. Methods: Thirty eyes of 30 subjects with DM1, with no sign of retinal vasculopathy, and 30 eyes of 30 age- and sex-matched healthy subjects were enrolled in this cross-sectional clinical study. Functional testing included Humphrey Matrix perimetry and white-on-white Humphrey visual field perimetry (HFA), while retinal nerve fibre layer (RNFL) thickness was measured by scanning laser polarimetry with variable corneal birefringence compensator (GDx VCC). Results: Matrix mean deviation (MD) was found to be significantly reduced in subjects with DM1 compared with controls (−1.10 (SD 2.98; 95% CI −2.21 to 0.01) vs 1.37 (SD 2.11; 95% CI 0.58 to 2.16), p = 0.0005). HFA MD and pattern standard deviation (PSD) were significantly worse in subjects with DM1 compared with controls (p = 0.010 and p = 0.013 respectively). Among structural parameters, average peripapillary RNFL thickness was reduced in DM1 subjects (p = 0.006). Matrix MD and HFA MD and PSD, and average peripapillary and superior RNFL, were significantly reduced in subjects with DM1 with HbA1c ⩾7% compared with controls. Conclusions: Functional and structural retinal testing by Humphrey Matrix and GDx VCC could be useful for the identification of early retinal impairment in people with DM1 with no sign of retinal vasculopathy.


Biochemical and Biophysical Research Communications | 1985

Inhibition of insulin and epidermal growth factor (EGF) receptor autophosphorylation by a human polyclonal IgG

Renzo Cordera; Roberto Gherzi; Roberto De Pirro; Luciano Rossetti; Gary R. Freidenberg; Gabriella Andraghetti; Renato Lauro; Luciano Adezati

The immunoglobulin G of a polyclonal antiserum (pIgG) from a patient with insulin resistance and hypoglycemia was tested for its ability to inhibit insulin binding and to affect the autophosphorylation of partially-purified insulin receptors extracted from rat liver membranes. pIgG, when added 4 hr prior to insulin, inhibited subsequent insulin binding by 50% at 30 micrograms added protein; however, insulin previously bound to the receptor could not be displaced by a 4 hr subsequent exposure of up to 70 micrograms pIgG. pIgG, independent of its effect on insulin binding, inhibited both basal and insulin-stimulated autophosphorylation of the insulin receptor in a dose-dependent manner with a half maximal effect at 3.3 to 7 micrograms protein. Furthermore, pIgG also reduced basal autophosphorylation of the EGF receptor. The effect of pIgG to inhibit basal autophosphorylation of insulin and EGF receptors, together with its ability to reduce autophosphorylation of insulin receptors fully occupied by insulin, imply that the effect of pIgG on receptor autophosphorylation is largely independent of its effect on ligand binding. Moreover, these findings suggest that pIgG may inhibit autophosphorylation by acting on domains which are similar in the insulin and EGF receptors.


Molecular and Cellular Endocrinology | 1987

Regulation of insulin receptor-associated tyrosine kinase by a polyclonal IgG.

Roberto Gherzi; Renzo Cordera; Gabriella Andraghetti; Roberto De Pirro; Gary R. Freidenberg; Renato Lauro; Luciano Adezati

The effect of a polyclonal anti-insulin receptor antibody (pIgG) on the insulin receptor tyrosine kinase (IRTK) activity toward poly-(Glu-Tyr) was examined using wheat germ agglutinin agarose-purified insulin receptors from rat liver membranes. The main effect of pIgG was a reduction of Vmax (from 60.8 to 31.8 pmol/min/mg), without changes of Km, when IRTK was activated by insulin. In contrast, when IRTK was activated by ATP preincubation, pIgG was unable to affect the reaction, suggesting that IRTK possesses at least two regulatory mechanisms, one of which can be affected by pIgG.


Journal of Endocrinological Investigation | 1987

Characterization of differences in insulin receptors from young and old red blood cells.

Antonio Camagna; L. Rossetti; R. De Pirro; M. Di Franco; Renato Lauro; Paola Samoggia; Patrizia Caprari; Giuseppe Salvo

It has been demonstrated that young RBCs (reticulocytes and early mature erythrocytes) possess more insulin receptors than old RBCs (late mature erythrocytes) but it is not yet known whether insulin receptors on young and old RBCs are regulated similarly. In the present investigation insulin receptors on young and old RBCs have, therefore, been studied in five normal male subjects before and after 2 days dexamethasone ingestion (0.5 mg tablet every 6 h) and, in the same subjects, before and 5 h after ingestion of 75 g glucose. The results obtained clearly demonstrate that dexamethasone increases insulin receptor concentration while glucose ingestion increases both insulin receptor affinity and concentration on young RBCs. By contrast, neither stimuli modify insulin receptors on old RBCs. Studies on RBCs are usually performed on the whole RBC population not taking into account this differential responsiveness of receptors on young versus old RBCs; consequently, this phenomenon might be responsible of the fact that some data reported on RBCs are not in agreement with those reported on monocytes or adipocytes and it should be taken into consideration when using RBCs to evaluate insulin receptor regulation.


Biochemical and Biophysical Research Communications | 1986

Insulin-like growth factor I (IGF I) receptor autophosphorylation and kinase activity. Effect of a human polyclonal antibody (pIgG)

Renzo Cordera; Roberto Gherzi; Roberto De Pirro; Gabriella Andraghetti; Gary R. Freidenberg; Francesco Minuto; Renato Lauro; G. Giordano; Luciano Adezati

IGF I receptor is a tyrosine kinase capable of phosphorylating the receptor itself and other substrates. A high degree of homology does exist in tyrosine kinase domain among receptors for several polypeptide growth factor receptors and this enzymic activity has been indicated as a possible mediator of biological action. Nevertheless growth factor receptors possess peculiar specificities both in their functions and tissue distribution. A human polyclonal IgG (pIgG), previously characterized as anti insulin receptor antibody, able to inhibit insulin receptor kinase activity, was used to further investigate subunit homologies and differences in antigenicity and functional regulation between IGF I and insulin receptors, IGF I receptor tyrosine kinase was stimulated by a IGF I analog (aIGF I), produced by DNA recombinant technology, pIgG was able to inhibit IGF I receptor kinase activity, thus revealing antigenic homologies between the kinase domains of insulin and IGF I receptors. However the more pronounced inhibition of IGF I receptor-compared with insulin receptor kinase activity by pIgG suggests the existence of different regulatory mechanisms.


Diabetes | 2004

The −866A/A Genotype in the Promoter of the Human Uncoupling Protein 2 Gene Is Associated With Insulin Resistance and Increased Risk of Type 2 Diabetes

Monica D'Adamo; Lucia Perego; Marina Cardellini; Maria Adelaide Marini; Simona Frontoni; Francesco Andreozzi; Angela Sciacqua; Davide Lauro; Paolo Sbraccia; Massimo Federici; Michele Paganelli; Antonio E. Pontiroli; Renato Lauro; Francesco Perticone; Franco Folli; Giorgio Sesti


Diabetes Care | 2005

C-174G Polymorphism in the Promoter of the Interleukin-6 Gene Is Associated With Insulin Resistance

Marina Cardellini; Lucia Perego; Monica D'Adamo; Maria Adelaide Marini; Cristina Procopio; Marta Letizia Hribal; Francesco Andreozzi; Simona Frontoni; Maurizio Giacomelli; Michele Paganelli; Antonio E. Pontiroli; Renato Lauro; Franco Folli; Giorgio Sesti


Thrombosis and Haemostasis | 2002

Increased superoxide anion production by platelets in hypercholesterolemic patients.

Valerio Sanguigni; Pasquale Pignatelli; Daniela Caccese; Fabio M. Pulcinelli; Luisa Lenti; Roberta Magnaterra; Francesca Martini; Renato Lauro; Francesco Violi


European Journal of Pharmacology | 1980

Effects of prazosin on the cAMP system in the spontaneously hypertensive rat (SHR) aorta.

Massimo D'Armiento; Franco Lacerna; Renato Lauro; Andrea Modesti; Roberto Verna; Giovanni Ceccarelli


Archive | 2006

Aterosclerosi e diabete: due facce della stessa medaglia

Massimo Federici; Stefano Rizza; Renato Lauro

Collaboration


Dive into the Renato Lauro's collaboration.

Top Co-Authors

Avatar

Massimo Federici

University of Rome Tor Vergata

View shared research outputs
Top Co-Authors

Avatar

Davide Lauro

University of Rome Tor Vergata

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Marta Letizia Hribal

University of Rome Tor Vergata

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Roberto De Pirro

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge